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Abstract We examined the impact of co-occurring dia-
betes and hopelessness on 3-year prognosis in percutaneous
coronary intervention patients. Consecutive patients
(n = 534) treated with the paclitaxel-eluting stent com-
pleted a set of questionnaires at baseline and were followed
up for 3-year adverse clinical events. The incidence of
3-year death/non-fatal myocardial infarction was 3.5% in
patients with no risk factors (neither hopelessness nor
diabetes), 8.2% in patients with diabetes, 11.2% in patients
with high hopelessness, and 15.9% in patients with both
factors (p = 0.001). Patients with hopelessness (HR: 3.28;
95% CI: 1.49–7.23) and co-occurring diabetes and hope-
lessness (HR: 4.89; 95% CI: 1.86–12.85) were at increased
risk of 3-year adverse clinical events compared to patients
with no risk factors, whereas patients with diabetes were at
a clinically relevant but not statistically significant risk
(HR: 2.40; 95% CI: 0.82–7.01). These results remained,
adjusting for baseline characteristics and depressive
symptoms. These findings testify to the importance of
identifying patients with co-occurring risk factors, as they
likely require special management in clinical practice in
addition to standard medical treatment.
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Introduction
Patients with co-morbid diabetes and coronary artery dis-
ease (CAD) have a higher risk for adverse prognosis and
restenosis following successful percutaneous coronary
intervention (PCI), due to manifestations of CAD being
more severe in patients with diabetes (The Bari Investi-
gators 1997; Detre et al. 1999; Buse et al. 2007). Psycho-
social factors, such as depression and hopelessness, may
enhance this risk. In CAD, depression has been associated
with multiple adverse health outcomes, including increased
mortality (Barth et al. 2004; de Jonge et al. 2006; Jiang
et al. 2001), re-hospitalizations (Jiang et al. 2001), poor
health status (Rumsfeld et al. 2003; Ruo et al. 2003), and
non-compliance (Dimatteo et al. 2000). Similarly, in
patients with diabetes, depression contributes to increased
morbidity and mortality (Ciechanowski et al. 2000),
decreased quality of life (Hanninen et al. 1999), and poor
glycemic control (Gary et al. 2000).
Studies have examined the separate influence of diabetes
and depression on clinical outcome in CAD rather than
their co-occurrence or adjusted statistically for one factor
while examining the impact of the other. However,
co-occurring diabetes and depression likely incur a higher
risk of adverse clinical events than the presence of one of
the factors (Rozanski et al. 2005). In a recent study of PCI
patients, we found that diabetes predicted the onset of
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depressive symptoms at 12 months in patients free of
symptoms at 6 months (Pedersen et al. 2006), suggesting
that patients with co-occurring diabetes and CAD may
comprise high-risk patients. In the recent enhancing
recovery in coronary heart disease patients (ENRICHD)
trial on patients with increased psychosocial risk (i.e.,
being either depressed or having low perceived social
support, or both), both diabetes and depression were
independent predictors of death or non-fatal myocardial
infarction (MI), but the study did not examine whether
depression modulates the impact of diabetes on outcome
(Jaffe et al. 2006). By 2015, 30% of all revascularization
procedures in the US are estimated to be undertaken in
patients with diabetes (Kapur et al. 2005). Hence, knowl-
edge of a potential combined adverse effect of diabetes and
depression on prognosis in patients treated with PCI is
important for secondary prevention.
In the studying of the co-occurrence of diabetes and
depression on prognosis, we have chosen to focus on
hopelessness rather than depression per se. Although
hopelessness may be considered a feature of depression, it
is neither a necessary nor a sufficient criterion for a clinical
diagnosis of depression according to DSM-IV criteria. In
addition, it correlates weakly with standard depression
scales, and therefore may deserve studying in its own right
(Everson et al. 1996). Others have also found that hope-
lessness is associated with reduced survival in a mixed
group of CAD patients (Barefoot et al. 2000). In addition,
the studying of hopelessness fits in well with the ongoing
quest for the identification of the nature of depressive
symptoms and those that have the most adverse effect on
prognosis (de Jonge et al. 2006). Hence, the aim of the
current prospective 3-year follow-up study was to examine
the impact of co-occurring diabetes and hopelessness on
prognosis in PCI patients, adjusting for a standardized
measure of depressive symptoms.
Materials and methods
Patients and design
Consecutive patients with stable or unstable angina,
undergoing PCI with the paclitaxel-eluting stent as the
default strategy (i.e., 88.8% of the current sample was
treated with the paclitaxel-eluting stent) at the Erasmus
Medical Center, Rotterdam, The Netherlands, between July
1, 2003 and July 1, 2004, comprised the patient sample for
the current study. The study design has been described
elsewhere (Pedersen et al. 2007). In brief, 710 patients
were approached in writing 4 weeks post-PCI (referred to
as baseline in the remainder of the article) and asked to
complete a set of standardized and validated question-
naires, of whom 536 (75% response rate) agreed.
Responders and non-responders differed on smoking and
dyslipidemia, with non-responders being more likely to
smoke (22% vs. 14%; p = 0.003) but less likely to suffer
from dyslipidemia (63% vs. 74%; p = 0.001) than
responders. No other differences were found between non-
responders and responders on baseline characteristics,
including cardiac medication. Since two patients had not
responded to the item assessing hopelessness in the current
study, statistical analyses are based on 534 patients.
The hospital medical ethics committee approved the
study protocol. The study was carried out conform to the
Helsinki Declaration.
Measures
Demographic and clinical characteristics
Demographic variables comprised sex, age, and marital
status. Information on clinical variables, including indica-
tion for PCI (stable vs. unstable angina), stent type (pac-
litaxel-eluting stent vs. other), multi-vessel disease, cardiac
history [MI, coronary artery bypass graft surgery (CABG)
or PCI prior to the index PCI], hypertension, dyslipidemia,
diabetes mellitus, smoking, and cardiac medication (aspi-
rin, beta-blockers, ACE-inhibitors, diuretics, and statins)
was obtained from the medical records. Hypertension,
dyslipidemia and diabetes mellitus were considered present
if patients were treated for the condition.
Hopelessness
Hopelessness was assessed with the item ‘‘Have you
experienced a feeling of hopelessness recently?’’ of the
Maastricht Questionnaire at baseline (Appels et al. 1987).
The item is answered on a 3-point scale (0 = no; 1 = ?;
2 = yes). This item has been shown to be of prognostic
value in PCI patients, with patients responding with a 1 or
2 to the item being defined as suffering from hopelessness
(Pedersen et al. 2007). Previous studies have also used 1 or
2 items to assess hopelessness as a risk factor for the onset
of CAD (Everson et al. 1996; Pollitt et al. 2005; Everson
et al. 1997) and prognosis in CAD (Pedersen et al. 2007).
Depressive symptoms
We used the depression subscale of the Hospital Anxiety
and Depression Scale (HADS) to evaluate the presence of
depressive symptoms at baseline (Zigmond and Snaith
1983; Spinhoven et al. 1997). The subscale consists of 7
items that are answered on a 4-point Likert scale from 0 to
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3 (score range 0–21). A cut-off C8 on the subscale was
used to indicate patients with likely depressive symptom-
atology, as this represents an optimal balance between
sensitivity and specificity (Bjelland et al. 2002). The sub-
scale is a valid and internally consistent measure of
depressive symptoms, with Cronbach’s alphas ranging
from 0.67 to 0.90 across 15 studies (Bjelland et al. 2002).
An advantage of using the HADS in the context of CAD is
that the measure is largely devoid of somatic items,
decreasing the chance that scores are confounded by car-
diac disease severity (Herrmann 1997).
Clinical outcome
Clinical outcome was defined as a cumulative endpoint of
either death (all-cause) or non-fatal MI 3 years post-PCI. If
patients would experience more than one event during the
follow-up period, the first occurring event would count.
The municipal civil registry was contacted to ascertain the
survival status of every patient. Information on non-fatal
MIs was obtained from the medical records, using an
increase in the creatine kinase-MB fraction of 3 times the
upper limit of normal as the defining criteria, according to
guidelines of the American Heart Association and the
American College of Cardiology (Smith et al. 2006; Smith
et al. 2001).
Statistical analysis
The correlation between hopelessness and depressive
symptoms at baseline was examined with Spearman’s rho
(q), since the scale related to hopelessness was at an
ordinal level. To ascertain the impact of co-occurring
versus single risk factors, four groups were formed on the
basis of the risk factors diabetes and hopelessness, as fol-
lows: (1) No risk factors (neither diabetes nor hopeless-
ness); (2) Diabetes only; (3) Hopelessness only; (4) Co-
occurring diabetes and hopelessness. Baseline characteris-
tics stratified by diabetes and hopelessness were compared
with the Chi-square test (Fisher’s exact test when appro-
priate) for nominal variables and analysis of variance
(ANOVA) with a post-hoc Bonferroni correction for con-
tinuous variables. Univariable and multivariable Cox
regression analyses were used to determine the impact of
the four risk groups on clinical outcome at 3 years, using
the no risk group as the reference category. A priori, the
covariates sex, age, multi-vessel disease, cardiac history
(MI, PCI or CABG prior to the index PCI), hypertension,
dyslipidemia, and smoking were chosen for inclusion in the
multivariable analyses based on the literature. Baseline
variables on which the four risk groups differed were also
entered as covariates, as they may potentially serve as
confounders on the impact of the four risk groups on
clinical events. In addition, we entered depressive symp-
toms, using a cut-off C8 on the HADS at baseline, to
ascertain that hopelessness exerted an independent effect of
depressive symptoms on clinical outcome. Hazard ratios
(HR) with their associated 95% confidence intervals (CI)
are reported. A p-value \0.05 was used to indicate statis-
tical significance. All tests were two-tailed. All analyses
were performed using SPSS 14.0 for Windows (SPSS Inc.,
Chicago, Illinois).
Results
Relationship between hopelessness and depressive
symptoms
The correlation between hopelessness and depressive
symptoms at baseline was q = 0.43 (p \ 0.001), indicating
a shared variance of 18%. There was no indication that the
correlation between hopelessness and depressive symptoms
was larger in patients with multi-vessel disease (n = 321;
q = 0.41; p \ 0.001) compared to patients with no multi-
vessel disease (n = 213; q = 0.47; p \ 0.001).
Number of events at 3-year follow-up
In total 38 patients experienced either a non-fatal MI or
died during the 3-year follow-up period, with one patient
experiencing both events, with the non-fatal MI preceding
death in this patient. For statistical analyses, the first
event, that is the non-fatal MI, counted towards the end-
point.
Baseline characteristics
Baseline characteristics stratified by diabetes and hope-
lessness are shown in Table 1. Differences were found
between risk factor groups on age, multi-vessel disease,
hypertension, dyslipidemia, current smoking, and the use
of ACE-inhibitors. Patients with diabetes were older, more
likely to have hypertension and dyslipidemia than the other
three groups, whereas high hopelessness patients were
more likely to smoke and use ACE-inhibitors. Patients with
co-occurring diabetes and hopelessness were more likely to
have multi-vessel disease. No other differences on demo-
graphic and clinical baseline characteristics were found
between groups.
The prevalence of depressive symptoms at baseline,
using the standardized cut-off C8 on HADS [25], was
13.0% in patients with neither risk factors, 16.4% in
patients with diabetes, 48.6% in the high hopelessness
296 J Behav Med (2009) 32:294–301
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patients, and 50% in patients with co-occurring diabetes
and hopelessness (p \ 0.001; Fig. 1). Hence, we added
depressive symptoms at baseline as a covariate to the
multivariable Cox regression analysis.
Incidence of clinical events 3-year post-PCI stratified
by diabetes and hopelessness
The incidence of death or non-fatal MI at follow-up differed
significantly between the four risk groups, with 3.5% in
patients with no risk factors (neither diabetes nor hope-
lessness), 8.2% in patients with diabetes, 11.2% in the high
hopelessness patients, and 15.9% in patients with
co-occurring hopelessness and diabetes (p = 0.001; Fig. 2).
In univariable analysis using the no risk factor group as the
reference category, patients with hopelessness (HR: 3.28;
95% CI: 1.49–7.23; p = 0.003) and co-occurring diabetes
and hopelessness (HR: 4.89; 95% CI: 1.86–12.85; p =
0.001) were at increased risk of 3-year adverse clinical
events compared to patients with no risk factors, whereas
patients with diabetes had a clinically relevant risk although
it was not statistically significant (HR: 2.40; 95% CI: 0.82–
7.01; p = 0.11).
Table 1 Patient characteristics stratified by hopelessness and diabetes*
None (n = 286) Diabetes (n = 61) Hopelessness (n = 143) Co-occurrence (n = 44) p
Demographics
Males 217 (75.9) 40 (65.6) 98 (68.5) 30 (68.2) 0.21
Age, mean (SD) 63.7 (10.6) 67.4 (10.4) 60.3 (11.5) 64.2 \0.001
Single/no partner 51 (18.0) 15 (25.0) 27 (19.0) 9 (20.9) 0.65
Indication for PCI
Unstable angina 137 (47.9) 25 (41.0) 63 (44.1) 21 (47.7) 0.73
Stent type
Paclitaxel-eluting stenta 254 (88.8) 52 (85.2) 132 (92.3) 37 (84.1) 0.31
Clinical variables
Multi-vessel disease 167 (58.4) 42 (68.9) 76 (53.1) 36 (81.8) 0.003
Cardiac historyb 145 (50.7) 35 (57.4) 87 (60.8) 28 (63.6) 0.14
Hypertension 124 (43.4) 48 (78.7) 54 (37.8) 30 (68.2) \0.001
Dyslipidemia 202 (70.6) 56 (91.8) 98 (68.5) 39 (88.6) \0.001
Current smoking 36 (12.6) 5 (8.2) 30 (21.0) 4 (9.1) 0.032
Cardiac medication
Aspirin 276 (96.5) 58 (95.1) 132 (92.3) 42 (95.5) 0.29
Beta-blockers 58 (20.3) 13 (21.3) 37 (25.9) 10 (22.7) 0.62
ACE-inhibitors 13 (4.5) 6 (9.8) 23 (16.1) 7 (15.9) \0.001
Diuretics 4 (1.4) 1 (1.6) 3 (2.1) 1 (2.3) 0.86
Statins 211 (73.8) 43 (70.5) 109 (76.2) 35 (79.5) 0.72
* Values are expressed as n (%) unless otherwise specified
a The paclitaxel-eluting stent (PES) was used as the default strategy (i.e., in 88.8% of the total sample); other stents used were the sirolimus-
eluting stent (SES; 4%), both PES and SES (1%), or bare metal stent/balloon dilation (6%)
b MI, PCI or CABG prior to the index PCI
Fig. 1 Prevalence of depressive symptoms (cut-off C8) at baseline
stratified by diabetes and hopelessness (total numbers are listed on top
of bars; two patients had no score on the HADS, hence this analysis is
based on n = 532)
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Impact of diabetes and hopelessness on 3-year clinical
events (adjusted analysis)
Results of the impact of co-occurring versus single risk
factors are shown in Table 2. Patients with co-occurring
diabetes and hopelessness (HR: 5.12; 95% CI: 1.79–14.64;
p = 0.002) remained at the highest risk for adverse prog-
nosis at 3 years, followed by high hopelessness patients
(HR: 3.45; 95% CI: 1.48–8.01; p = 0.004), adjusting for
demographic (sex and age) and clinical factors (multi-
vessel disease, CAD history, hypertension, dyslipidemia,
smoking, and ACE-inhibitors) and depressive symptoms at
baseline. Diabetes as a single risk factor again fell short of
significance (HR: 2.28; 95% CI: 0.75–6.96; p = 0.15).
Depressive symptoms (HR: 0.68; 95% CI: 0.32–1.45;
p = 0.32) were not a significant predictor of prognosis, but
there was a trend for CAD history (HR: 1.92; 95% CI:
0.89–4.14; p = 0.096).
In order to further examine the relationship found for the
impact of single risk factors (i.e., diabetes or hopelessness)
versus co-occurring diabetes and hopelessness, we used the
Wald statistics to test the statistical significance of each
coefficient. All differences between the risk factor groups
were significant (ps \ 0.05).
Discussion
In the current study, we examined the impact of
co-occurring diabetes and hopelessness on prognosis in
patients with established CAD in general and PCI patients
treated with drug-eluting stents in particular. The 3-year
incidence of death/MI was highest in patients with
co-occurring risk factors (15.9%), followed by the high
hopelessness patients (11.2%), patients with diabetes
(8.2%), and patients with no risk factors (i.e., neither dia-
betes nor hopelessness; 3.5%). Patients with co-occurring
diabetes and hopelessness were at a 5-fold risk of death or
non-fatal MI at 3 years, with the risk to patients with a
single risk factor (i.e., diabetes or hopelessness) being 2- to
3-fold compared to patients with no risk factors, controlling
for demographic and clinical risk factors and depressive
symptoms at baseline.
Psychosocial risk factors are known to cluster together
within individuals and also to act in synergy with tradi-
tional risk factors for CAD (Rozanski et al. 2005). In
addition, mood disorders, such as depression, have been
shown to exacerbate the burden of physical illness (Fenton
and Stover 2006) and to lead to more extensive health-care
use in the physically ill (Stein et al. 2006), with co-morbid
depression and diabetes also increasing the risk of mor-
tality compared to patients with depression or diabetes
alone (Egede et al. 2005). Similar to a population-based
study of 10,025 individuals showing that co-occurring
diabetes and depression was associated with a greater risk
for cardiac- and all-cause mortality compared with the
single risk factors alone (Egede et al. 2005), we found that
co-occurring diabetes and hopelessness incurred the high-
est risk of a composite of mortality and non-fatal MI
3 years post-PCI.
Fig. 2 Risk of death or non-fatal myocardial infarction 3 years post-
PCI (total numbers are listed on top of bars)
Table 2 Impact of diabetes and hopelessness on 3-year clinical
events (adjusted analysis)
HR [95% CI] p
Diabetes* 2.28 [0.75–6.96] 0.15




Depressive symptoms (baseline) 0.68 [0.32–1.45] 0.32
Male sex 1.02 [0.48–2.16] 0.95
Age 1.02 [0.99–1.06] 0.15
Multi-vessel disease 1.81 [0.78–4.16] 0.17
Cardiac history 1.92 [0.89–4.14] 0.10
Hypertension 0.95 [0.47–1.91] 0.88
Dyslipidemia 0.59 [0.28–1.23] 0.16
Smoking 0.91 [0.30–2.77] 0.86
ACE-inhibitors 1.53 [0.65–3.56] 0.33
* No risk group (neither diabetes nor hopelessness) = reference
category
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It is noteworthy that hopelessness and co-occurring
diabetes and hopelessness had an impact on prognosis
above and beyond depressive symptoms at baseline. How-
ever, this finding is consistent with the results of others,
showing that hopelessness predicts mortality in CAD
patients (Pedersen et al. 2007) and the incidence of cancer,
MI, and mortality in the general population independent of
depression (Everson et al. 1996). In addition, others have
shown that hopelessness correlates weakly with depression
(Everson et al. 1996), which was also confirmed in the
current study with an overlap in variance of 18%. These
results testify to the prognostic properties of hopelessness
and emphasize the importance of studying hopelessness in
its own right (Everson et al. 1996; Breitbart et al. 2000).
Further research into hopelessness and its potential mech-
anisms also fits in well with the ongoing quest for the
identification of the depressive symptoms that have the
most adverse effect on prognosis (de Jonge et al. 2006).
In clinical practice, identifying patients who score high
on hopelessness can easily be done with the 1-item mea-
sure of the MQ used in the current study. Alternatively, the
2-item patient health questionnaire (PHQ-2; Lo¨ve et al.
2005) and the 4-item Symptoms of mixed Anxiety-
Depression index (SAD4; Denollet et al. 2006) both com-
prise an item assessing hopelessness. The former measure
has been shown to be sensitive to change and the latter to
predict major depressive disorder, adjusting for depressive
symptoms. From a treatment point of view, enhancing
partner support or patients’ perception of this support may
increase a sense of optimism and reduce hopelessness
(Gustavsson-Lilius et al. 2007). Cognitive behavioral
therapy may well form the key to changing patients’ per-
ception, although it may be necessary to use it in combi-
nation with anti-depressant treatment in more severe cases.
Although conducted in college students, a recent random-
ized controlled trial using a brief mailed intervention for
depressive symptoms as the mainstay of treatment also
offers hope to patients characterized by feelings of hope-
lessness (Geisner et al. 2006). The latter study showed that
a reduction in depressive symptoms was partly mediated by
a reduction in hopelessness, emphasizing the importance of
the therapist instilling hope of change in patients. Future
intervention studies should see if current interventions
impact on hopelessness as a way to improve clinical out-
comes and quality of life.
This study has some limitations. First, 25% of patients
declined to participate, and non-responders differed on
smoking and dyslipidemia, although not on any of the other
demographic and clinical baseline characteristics. Second,
the sample consisted of patients with stable or unstable
angina as indication for PCI, and the results may not
generalize to patients with acute MI. Nevertheless, psy-
chosocial factors have been shown to predict mortality in
these patients, emphasizing the relevance of also studying
the impact of co-occurring risk factors in MI patients
(Lespe´rance et al. 2000). Our results support this notion.
Third, we cannot rule out the possibility that the impact of
diabetes on prognosis may be due to lack of adherence,
which we did not assess. Adherence to cardio-protective
medication in patients with co-morbid diabetes and CAD
has been linked to prognosis (Ho et al. 2006). We also had
no information on health-related behaviors, such as phys-
ical activity and dietary intake, which could mediate the
relationship between hopelessness and clinical events.
Fourth, we had no information on the use of psychotropic
medication, such as anti-depressants, and participation in
cardiac rehabilitation, which could potentially serve as
confounders. Fifth, the number of events was relatively
small with 38 deaths and non-fatal MIs, which means that
essentially the multivariable model was overfitted. It is
possible that given more events, diabetes as a single risk
factor would also have been significantly associated with
prognosis in the current study. Sixth, the measures were
obtained 4 weeks post-procedure, with the possibility that a
healthy survivor effect could exist. However, logistically it
was not possible to assess patients closer to the index event.
In addition, there is no consensus as to the most optimal
time point for assessing psychological distress, including
depression, in cardiac patients (Nicholson et al. 2006). In
fact, a recent study of depression in PCI patients showed
that baseline assessment was a less strong predictor of
subsequent depression compared to assessment at 1 month
(Poston et al. 2003).
In conclusion, co-occurring diabetes and hopelessness
was associated with a 5-fold increased risk of 3-year
prognosis post-PCI, controlling for baseline demographic
and clinical risk factors and depressive symptoms. The risk
incurred by the co-occurrence of these two risk factors was
higher than that for the single risk factors (i.e., diabetes and
hopelessness). These findings testify to the importance of
identifying patients with co-occurring risk factors, as they
likely require special management in clinical practice
including additional intervention, e.g., of a behavioral nat-
ure, in addition to pharmacological treatment. It now seems
timely to shift our focus from studying the impact of single
risk factors on prognosis to their co-occurrence, focusing on
risk factors of both a clinical and psychosocial nature.
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